BTK and B-cell chronic lymphocytic leukemia: Disrupting BCR signaling by BCR-associated kinase inhibition, e.g., BTK or SYK, lead to cross-talk blockage within the microenvironment and thus of BCR signaling [30], which makes SYK inhibition in CLL highly effective.